Discriminative value of CA-125, HE4, Risk of Malignancy Index II (RMI-II) and Risk of Malignancy Algorithm (ROMA) in the differential diagnosis of pelvic masses: conclusions from a referral Centre in Portugal
Authors:
- 8 June 2018
- journal article
- research article
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 38 (8) , 1140-1145
Abstract
The major purpose of this article was to compare the discriminative value of different algorithms and serum biomarkers in the differential diagnosis of adnexal masses. We performed a retrospective study with 247 women with adnexal neoplasia, submitted to surgical treatment and with a histological diagnosis. The evaluation of the area under the curve (AUC) for isolated CA-125 and HE4, and for ROMA and RMI-II, showed a better specificity of HE4 and RMI-II in premenopausal women. In the postmenopausal group, ROMA and RMI-II were the algorithms with a better performance.Keywords
This publication has 19 references indexed in Scilit:
- A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancerGynecologic Oncology, 2014
- Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal womenAmerican Journal of Obstetrics and Gynecology, 2011
- No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical settingGynecologic Oncology, 2011
- HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy AlgorithmBritish Journal of Cancer, 2011
- Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic massAmerican Journal of Obstetrics and Gynecology, 2010
- Comparison of four malignancy risk indices in the preoperative evaluation of patients with pelvic massesEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2009
- A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic massGynecologic Oncology, 2009
- Carcinoma of the OvaryInternational Journal of Gynecology & Obstetrics, 2006
- Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre‐operative diagnosis of pelvic massesBJOG: An International Journal of Obstetrics & Gynaecology, 1996
- A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancerBJOG: An International Journal of Obstetrics & Gynaecology, 1990